Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ramipril + indapamide is a fixed-dose combination pharmaceutical composition used for the treatment of hypertension. It combines two antihypertensive agents with complementary mechanisms of action: ramipril, an angiotensin-converting enzyme (ACE) inhibitor, and indapamide, a thiazide-like diuretic. Ramipril works by inhibiting the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, thereby reducing peripheral vascular resistance and aldosterone secretion. Indapamide acts primarily on the distal convoluted tubules of the kidney to inhibit the sodium-chloride symporter, promoting the excretion of sodium and water and reducing peripheral vascular resistance through a direct vasodilatory effect. This combination is particularly effective for patients whose blood pressure is not adequately controlled by monotherapy, providing synergistic blood pressure reduction and potentially reducing the risk of cardiovascular events such as stroke and myocardial infarction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ramipril + indapamide.